Gastrointestinal Endoscopy
Volume 71, Issue 6 , Pages 998-1005, May 2010

Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy

Current affiliations: VA Medical Center (M.S., N.M., U.K.M. A.A.), Center for Outcomes Research (N.N.), SUNY Upstate Medical University (M.S., N.M., U.K.M., A.A.), Syracuse, New York, University of Rochester Medical Center (V.K.), Rochester, New York

Received 15 September 2009; accepted 12 November 2009. published online 12 March 2010.

Background

The risk of postpolypectomy bleeding (PPB) in patients undergoing colonoscopy on uninterrupted clopidogrel therapy has not been established.

Objective

To assess the PPB rate and outcome and identify risk factors associated with PPB in patients taking clopidogrel.

Design

Single-center, retrospective study. Demographics, clinical parameters, polyp characteristics, polypectomy techniques, and postpolypectomy events in the groups were compared by univariate analysis. Stepwise logistic regression analyses identified independent risk factors associated with PPB.

Setting

Veterans Affairs Medical Center.

Patients

A total of 142 patients (375 polypectomies) taking clopidogrel (cases) and 1243 patients (3226 polypectomies) not taking clopidogrel (controls).

Interventions

None.

Main Outcome Measurements

Postpolypectomy bleeding, hospitalization, and mortality.

Results

The immediate (intraprocedural) bleeding rate was similar in the 2 groups (2.1% vs 2.1%). Delayed (postprocedural) PPB rate was higher in the group taking clopidogrel (3.5% vs 1.0%, P = .02). Delayed bleeding of significance requiring hospitalization and transfusion/intervention was also higher in patients taking clopidogrel (2.1% vs 0.4%, P = .04). The length of hospital stay and interventions for PPB were comparable between the 2 groups. There was no mortality. Concomitant use of clopidogrel and aspirin/other nonsteroidal anti-inflammatory drugs (odds ratio 3.7; 95% CI, 1.6-8.5) and the number of polyps removed (OR 1.3; 95% CI, 1.2-1.4) were the only significant risk factors associated with PPB. Clopidogrel alone was not an independent risk factor for PPB.

Limitations

Retrospective study and small number of patients with PPB.

Conclusions

The PPB rate is significantly higher in patients undergoing polypectomy while taking clopidogrel and concomitant aspirin/nonsteroidal anti-inflammatory drugs; however, the risk is small and the outcome is favorable. Routine cessation of clopidogrel in patients before colonoscopy/polypectomy is not necessary.

Abbreviations: ASA, aspirin, CAD, coronary artery disease, COPD, chronic obstructive pulmonary disease, CrCl, creatinine clearance, DM, diabetes mellitus, HTN, hypertension, NSAID, nonsteroidal anti-inflammatory drug, OR, odds ratio, PPB, postpolypectomy bleeding, PPI, proton pump inhibitor, VAMC, Veterans Affairs Medical Center

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 DISCLOSURE: All authors disclosed no financial relationships relevant to this publication.

 See CME section; p. 1028

PII: S0016-5107(09)02747-3

doi:10.1016/j.gie.2009.11.022

Gastrointestinal Endoscopy
Volume 71, Issue 6 , Pages 998-1005, May 2010